Drug Profile
PHP 303
Alternative Names: BAY 858501; PHP-303Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bayer HealthCare
- Developer Bayer HealthCare; Peak Bio
- Class Antibronchitics; Benzenesulfonates; Fluorinated hydrocarbons; Hepatoprotectants; Nitriles; Pyrimidines; Small molecules
- Mechanism of Action Leucocyte elastase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alpha 1-antitrypsin deficiency
- Phase I Non-alcoholic steatohepatitis
- Preclinical Adult respiratory distress syndrome
- No development reported Bronchiectasis
Most Recent Events
- 14 Nov 2022 Chemical structure information added
- 22 Jun 2022 Phase-I development is ongoing in Non-alcoholic steatohepatitis (In volunteers) in USA (PO) (pH Pharma pipeline, June 2022)
- 22 Jun 2022 Preclinical trials in Adult respiratory distress syndrome in USA (PO) (pH Pharma pipeline, June 2022)